Introduction
Adenocarcinoma of the pancreas remains a devastating disease. Pancreatic cancer is the 4th leading cause of cancer-related mortality in U.S. annually. The estimated incidence for 2009 was 42,470 new cases and 35,240 anticipated deaths [1] . At the time of diagnosis, 80% of patients have locally advanced or advanced disease for which no curative therapy exist. Seventy to 80% of patients treated with curative intent pancreaticoduodenectomy will recur within the first 2 years after surgical resection and will ultimately succumb to their disease [2] [3] [4] . As a result, the overall 5-year survival rate for all patients diagnosed with adenocarcinoma of the pancreas is less than 5%. Standard therapy for patients with advanced disease or for those who recur after surgical resection has been limited to gemcitabine, 5-fluorouracil (5-FU) and most recently erlotinib in combination with gemcitabine [5] [6] [7] . Unfortunately, the use of these drugs as single agents or in combination results in a median survival of less than 7 months. The increased understanding of pancreatic ductal adenocarcinoma biology has led to a number of phase III clinical trials that have combined gemcitabine with either biologic or modern cytotoxic agents but have not shown a survival benefit when compared to gemcitabine except for the modest survival benefit with the addition of capecitabine or erlotinib to gemcitabine [6] [7] [8] [9] [10] [11] . These disappointing results demonstrate the need for alternative approaches to the development of pancreatic cancer therapy.
Pharmacogenomics represents a novel approach to drug development that takes into account the pharmacokinetic variability in drug metabolism amongst individuals as a function of genetic polymorphisms in key drug metabolism genes, such as drug-metabolism enzymes and transport proteins [12] . An initial example of the successful application of pharmacogenomics to augment cancer therapy was demonstrated when this approach was applied to 5-FU dosing in patients with colorectal cancer. Thymidine synthase (TS) is one of the primary targets of the antimetabolite, 5-FU. It is a folate dependent enzyme that catalyzes the conversion of doxyuridine-5′-monophosphate to deoxythymidine-5′-monophosphate, representing the only de novo source of thymidine for DNA synthesis [13] [14] [15] . TS regulation is quite complex, but appears to be partially controlled by a polymorphism in the human TS gene enhancer region (TYMS). TYMS consists of variable number of copies of a 28-bp tandem-repeat sequence [16] . Alleles with up to nine copies of this 28-bp repeats have been described, with TYMS*2 [double tandem repeats (S/S)] and TYMS*3 [triple tandem repeats (L/L)] alleles being the most common alleles in the patient populations. The approximate frequency of the TYMS alleles are 20% (*2/*2), 30-55% (*2/*3) and 20-40% (*3/*3). Genotyping of the TYMS 28-bp tandem-repeat polymorphism, possesses the potential to be a predictive marker of response and toxicity associated with TS-targeted therapy [17, 18] .
5-Fluorouracil forms the backbone of chemotherapy for colorectal cancer and is also approved for use in pancreatic cancer. Overexpression of TS in colon cancer patients correlates with primary resistance to 5-FU therapy and poor prognosis. TYMS *3 homozygous colorectal cancer patients possess significantly higher TS expression than patients with either allele of TYMS *2. The TYMS *3/*3 patients have decreased response rates to 5-FU therapy and worse outcomes in comparison to patients harboring the TYMS *2/*2 alleles [16, 17] . More recently, TS polymorphisms have also been demonstrated to predict response to capecitabine in colorectal cancer [18, 19] . In this small retrospective analysis, Park et al. reported a response rate in patients with *2/*2 alleles of 75% as compared to those with *2/*3 or *3/*3 alleles (25% and 8%, respectively) [19] . However, patients with *2/*2 genotype were also more likely to develop grade 3 toxicity after capecitabine administration (100% versus 30-40%). Consistent with these findings, homozygous TYMS*2 expression in patients undergoing neoadjuvant 5-FU based chemoradiation is associated with 60% downstaging of tumors after neoadjuvant therapy compared to TYMS*3 (22%) [18] . This study demonstrated that phase II genotype-directed clinical trials are feasible and may improve patient outcomes.
Capecitabine (Xeloda®) is an oral pro-drug that is absorbed unchanged in the GI tract and subsequently undergoes a series of enzymatic conversions into 5-FU. Capecitabine has been shown to selectively upregulate thymidine phosphorylase (TP) in tumor cells, which in turn results in the final enzymatic conversion of capecitabine to 5-FU [20] . It has been approved for use in patients with metastatic breast, colon cancer, and pancreatic cancer and is being investigated in numerous other malignant histologic subtypes. In pancreatic cancer, single agent capecitabine resulted in 7% to 8% objective response rate and a 24% clinical benefit response [21] . The combination of gemcitabine and capecitabine failed to demonstrate an overall survival benefit when compared to gemcitabine in phase III evaluation of patients with advanced pancreatic cancer [6, 22] . However, the combination demonstrated significant improvement in progression free survival, whilst demonstrating a trend toward an overall survival benefit independent of patient performance status in one study. Subset analysis of the second study revealed an overall survival benefit for patients with good performance status. These data demonstrate that capecitabine does possess antitumor activity in pancreatic cancer. Therefore we hypothesized that capecitabine treatment of TYMS genotype-selected patients would improve the 6-month survival of patients with previously treated metastatic pancreatic cancer.
Gemcitabine is a prodrug that requires cellular uptake and intracellular phosphorylation in order to exert its mechanism of action [23, 24] . Gemcitabine is an antimetabolite and exerts its cytotoxic effect by incorporating into the DNA strand as the active dFdCTP; thereby, inhibiting DNA synthesis. DNA repair plays an important role in gemcitabine mediated cell death as it acts by inhibiting DNA synthesis. Therefore single nucleotide polymorphisms in gene involved in the DNA repair mechanisms have been evaluated as potential biomarkers of response to gemcitabine. Single nucleotide polymorphisms in the DNA repair genes ATM, RecQ1 and Rad54L have been shown to be associated with improved overall survival in pancreatic cancer patients treated with neoadjuvant gemcitabine based chemoradiation [25, 26] . This study analyzed polymorphism in ATM G60A and RecQ1 A159C in a population of metastatic pancreatic cancer patients treated with gemcitabine in attempt to extend the findings obtained in the neoadjuvant setting to the metastatic disease population.
To our knowledge, this clinical trial represents the first genotype-directed clinical trial in the advanced pancreatic adenocarcinoma patient population.
Methods

Patient and study design
Patient selection Patients were considered eligible for genetic TYMS screening if they met all of the following criteria: Age 18 or older; histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the pancreas: no prior capecitabine therapy; measurable disease; ability to give informed consent; no known second malignancies (other than carcinoma-in-situ of the cervix, superficial skin cancer or superficial bladder cancer); Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2; adequate hematologic (absolute neutrophil count (ANC) ≥ 1,500/mm 3 and platelets ≥100,000/mm 3 ), hepatic (AST/ALT ≤ 2.5×ULN [or ≤ 5× ULN if attributable to liver metastases] and total bilirubin ≤ 1.5 ULN) and renal function (creatinine within institutional limits of normal or creatinine clearance [CrCl] >50 mL/min calculated by the Cockcroft-Gault equation). Screened patients possessing TYMS *2/*2 allele were consider eligible for the treatment portion of the study with capecitabine if they had received at least one gemcitabine containing regimen for metastatic disease; alternatively, patients relapsing within 6 months of completion of gemcitabine-based adjuvant therapy were also eligible. Patients could not have received prior 5-FU or capecitabine-based metastatic disease therapy. Patients must have had adequate end organ function as noted above and have an ECOG performance status of ≤ 2.
Study design This study was designed as an open-label, non-randomized phase II study. The study protocol was approved by the Johns Hopkins Hospital Institutional Review Board, and all patients gave written consent before any study-specific procedures were performed. There were two different consent forms for screening and treatment. To avoid delays between first-and second-line treatment, and allow for delays in screening results due to technical and other factors, the screening population included both firstand second-line patients. Genetic screening was performed by testing DNA obtained from peripheral blood mononuclear cells for the presence of the *2/*2 allele of the thymidine synthase enhancer region. Those patients previously treated with gemcitabine who possessed the *2/*2 allele were then eligible to be treated with capecitabine in 2nd line setting. Within 2 weeks prior to capecitabine treatment initiation the patients were reconsented for treatment and underwent a clinical screening assessments, including a medical history and physical examination, ECG, chest x-ray and tumor measurements. Patients who underwent genetic screening and were not homozygous for the TYMS *2/*2 allele were followed for survival, but received treatment according to the management of their primary medical oncologist.
Patients were treated with oral capecitabine 1,000 mg/m 2 administered twice daily (2,000 mg/m 2 /d) on days 1 to 14 of a 21 day treatment cycle. Patients received a total of three cycles prior to measuring response to therapy as outlined by RECIST criteria. A physical examination, including an assessment of vital signs, physical measurements, and clinical laboratory tests (hematology and blood chemistry), were also performed at all study visits. Adverse events were monitored throughout the study and for 28 days after the last study treatment.
Toxicity assessment Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 3.0. Toxicities were identified by medical history, physical examination, and review of the laboratory studies performed. Capecitabine administration was adjusted or interrupted for treatment related adverse events of grade 2 or greater according to the capecitabine dose modification algorithm in the package insert.
SNP analysis All specimens were processed and analyzed in the CLIA approved pathology laboratory of Kathy Murphy at Johns Hopkins University. Genomic DNA was extracted from peripheral blood samples using the EZ1 BioRobot (Qiagen, Valencia, CA). Amplification of the thymidine synthase polymorphic region was carried out in 20 µl reactions using 1 µl DMSO and 1.5 U Taq Gold polymerase (Applied Biosystems Inc., Foster City, CA). Primers were 5′ FAM-GTGGCTCCTGCGTTTCCCCC 3′ (TS-F) and 5′ GAGCCGGCCACAGGCATG 3′ (TS-R2). One microliter of amplification product was added to a mixture of diformamide and ROX GS500 size standard (Perkin Elmer, Wellesley, MA) and denatured at 95°C for 2 min. Samples were then analyzed on an ABI 3100 Genetic Analyzer (Applied Biosystems Inc, Foster City, CA,).
The ATM G60A and RecQ1 A159C polymorphisms were detected using TaqMan genotyping assays (Applied Biosystems Inc, Foster City, CA). ATM (rs664143) reaction consisted of 1X TaqMan Universal PCR Mast Mix (Applied BioSystems Inc, Foster City, CA) and 1X ATM primer/probe mix (Applied Biosystems). RecQ1 (rs13035) reaction consisted of 1X TaqMan Universal PCR Mast Mix, 0.9 µM primers (Forward: CAATCTGGTTCTAAGAATA CAGGAGCTA, Reverse: GGCATATACATGCATAAAC CATCTTT), 0.25 µM probes (C-Probe: FAM-AGTAA CAGTCATATCAGG-MGB, T-Probe: VIC-AGTAACA TTCATATCAGGC-MGB). Reactions were set up in a final volume of 25 µl with 30 ng DNA in each reaction. Thermal cycling consisted of an initial denaturation of 95°C for 10 min, followed by 35 cycles of 92°C for 15 s and 60°C for 1 min, on TaqMan 7900 instrument (Applied BioSystems Inc, Foster City, CA). Directly after amplification, plates were analyzed using ABI Allelic Discrimination Plate Read and Analysis Software (Applied BioSystems Inc, Foster City, CA). Five percent of the samples were subjected to cycle sequencing, and all of the sequencing results were concordant with the TaqMan genotyping results.
Pharmacokinetic analysis Capecitabine pharmacokinetics studies were performed during cycle 1. Blood samples were taken pre-treatment and post-treatment at 0.25 h, 0.5 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h and 8 h. Trough levels were evaluated by obtaining samples within 30 min prior to the dose administration on days 2, 8 and 15 of cycle 1. Blood samples were processed by centrifugation at 1,000 g at 4°C for 10 min. For capecitabine samples, tetrahydrouridine, a cytidine deaminase inhibitor, was added at a final concentration of 400 nM to increase the stability of capecitabine and metabolites in plasma during storage in the freezer [27] [28] [29] . Analytical analysis of capecitabine and metabolites (5-fluoro-5′-deoxycytodine (5′DFCR), 5-fluoro-5′-dexoxyuridines (5′-DFUR) and 5-FU) were quantitated by LC/MS/ MS over the range of 50 ng/mL to 10,000 ng/mL of plasma [27] . Individual pharmacokinetic parameters were estimated by standard non-compartmental analysis using the WinNonlin version 5.0 (Pharsight Corporation, Mountain View, CA) (Gibaldi M, Perrier D: Pharmacokinetics (ed 2nd). New York, NY, Dekker, 1982).
Statistics Originally the study was designed to test the primary endpoint of increased 6-month survival rate, compared to historical controls, for patients treated with capecitabine in the second line setting. The planned sample size was 65 patients. With 65 patients, there was a 96% chance of observing at least one occurrence of an adverse event if the true risk of that event was 5% or greater. Assuming a frequency of the S/S variant of 15-20%, we expected to screen approximately 500 patients in order to obtain 65 eligible patients for the treatment portion of the study. Sixty-five treated patients were estimated to be sufficient to demonstrate a 15% increase in 6-month survival rate in patients receiving second line therapy for metastatic pancreatic cancer. The estimate was based on testing a null hypothesis that the true survival rate at 6 months is 15% with a power of 90%, assuming a onesided exact test for a single proportion; this assumes that all patients will be followed for at least 6 months. KaplanMeier methods were planned to estimate the survival data of the patients treated on the study. Unfortunately, due to small sample size the estimates of the survival data were not appropriate. Kaplan-Meier methods were used to estimate the survival data in the screened patient population. The association TYMS, ATM and RecQ1 polymorphism relative to survival in the screened patient population was analyzed using Mantel-Cox log-rank test. Ultimately, this study was closed early due to poor accrual and severe toxicity.
Results
Screened patients demographics
Between 1/1/05 and 1/1/08, a total of 80 patients with adenocarcinoma of the pancreas underwent genetic screening to assess the presence of TYMS *2/*2 allele. All tests were performed in a rapid manner with less than 2-week time period from obtaining sample to completion of analysis. The screened patient characteristics can be found in Table 1A . The screened patient received a wide variety of gemcitabine containing regimens in the first line setting to include combinations with cisplatin and erlotinib, cisplatin, oxaliplatin, bevacizumab and mitomycin C. The age of screened patients ranged from 42 years old to 81 years old (median 65) with an equivalent male/female ratio, and performance status was ECOG ≤1 in 94% of patients. Sixteen patients (20%) of the total 80 patients screened were found to possess the homozygous S/S allele. Only 17% of screened patients had undergone a previous pancreaticoduodenectomy. Thirty-seven patients (46%) and 22 patients (28%) possessed either the heterozygous or homozygous TYMS*3 allele, respectively, resulting in the generation of a triple 28-base pair repeat sequence (Table 2 ).
Capecitabine treatment of homozygous TYMS*2 patients
Four (25%) of the 16 patients expressing the homozygous *2/*2 TYMS allele were treated with capecitabine in the second line setting. Twelve of the 16 eligible patients possessed inadequate performance status to receive second line therapy, were treated on other protocols available at the institution, or were treated by their primary oncologist off study. The four patients treated on study possessed good baseline performance status (Table 1B) . Three of the four patients had stage III disease at diagnosis. All of these patients had received prior therapy with either radiation or surgery. Three of the four patients had received prior adjuvant chemotherapy. One patient received adjuvant 5-FU and two were treated with gemcitabine in this setting. All patients received an initial capecitabine dose of 1,000 mg/m 2 twice daily for days 1 to 14 of a 21 day cycle. However, dose modification was frequent due to toxicity ( Table 3 ). The number of cycles on treatment varied from one cycle to a maximum of three cycles in one patient. The median number of cycles administered to these patients was 1.5. The daily dose administered ranged from 1,300 mg/day to 3,600 mg/day. Pharmacokinetic exposure was analyzed for capecitabine and 5-FU in 2 of the 4 treated patients. Pharmacokinetic exposure was consistent with previous reports; however, high inter-patient variabil- ity was observed [30] [31] [32] . Interpretation of these results is limited due to the small sample size. Unfortunately, only one of the four treated patients were evaluable to assess the primary endpoint of 6 month overall survival; thereby, an accurate estimate of the survival data was untenable. However, there was a trend toward decreased median survival in patients with homozygous TYMS*2 alleles when compared to patients with either TYMS*2/*3 or homozygous TYMS*3 in the screened patient population of 80 7.2 months vs 9.6 months (p 0.08), respectively, Fig. 1 .
Capecitabine-induced toxicity
The results of current clinical study are consistent with previous reports of increased risk of toxicity associated with 5-FU therapy in patients possessing the homozygous TYMS*2 allele. The predominant grade 3 toxicities were non-hematologic (Table 3 ). Two of the four patients treated developed grade 3 hand and foot syndrome. The other two patients developed grade 3 diarrhea despite adequate supportive care. Three of the four patients developed grade 2 stomatitis and nausea vomiting. Only one patient was treated beyond cycle 2. Two patients were treated with only one cycle of chemotherapy due the development of grade 2 and 3 mucositis, vomiting and hand and foot syndrome resulting in hospitalization of one of these patients for supportive care. Neither of these patients remained on study beyond day 15 of therapy. One patient was taken off study in cycle 1 due to a combination of disease progression and toxicity, whilst the second patient withdrew consent to participate in the study because of the development nonhematologic toxicity within a single cycle of capecitabine dosing with dose modification. No grade 4 toxicities were observed. Hematologic toxicity in study consisted primarily of grade 1 anemia occurring in 3 of 4 treated patients. One patient experienced grade 2 neutropenia (Table 3) . In summary, capecitabine dosing in this patient population produced more non-hematologic severe toxicity than has previously been appreciated when dosing capecitabine in the unselected pancreatic adenocarcinoma population.
Gemcitabine response associated SNPs
The role of ATM and RecQ1 polymorphisms in the survival of patients with metastatic pancreatic cancer treated with gemcitabine was analyzed in the entire cohort of 80 patients enrolled to the molecular screening portion of this study.
There was no significant difference in overall survival with respect to G/G, G/A or A/A genotypes of ATM G60A. Accordingly, the median survival 9.1 months, 9.6 months and 9.0 months was not significantly different amongst the three groups (p=0.8), respectively for the G/G, G/A or A/A genotypes (data not shown). Next, RecQ1 A159C genotype was analyzed with respect to patient overall survival. The results of this analysis were not dissimilar to those obtained with the ATM G60A analysis. There was no association with RecQ1 A159C genotype and survival in the population of 80 screened gemcitabine refractory patient. Accordingly, the median survivals of 8.3 months, 9.0 months and 10.1 months for the respective RecQ1genotypes of A/A, A/C and C/C was not significantly different with a p-value of 0.832 (data not shown).
Discussion
Pancreatic cancer remains a devastating disease despite advances in the genetic characterization of the disease. 5-FU and gemcitabine remain the standard of care therapy for this disease. The addition of both cytotoxic and molecular based chemotherapies to these agents has resulted in minimal improvement in the clinical outcomes. These results suggest that alternative strategies must be taken to improve upon the effectiveness of these therapies. This clinical study represents the first attempt to use a genotypedirected strategy to improve the clinical outcome of 5-FU based therapy for pancreatic cancer patients. This study used the thymidylate synthase promoter TYMS*2 homozygous genotype to pre-select patients to receive capecitabine in the second-line setting. This strategy was adopted from the results of Park et al. demonstrating that the *2/*2 TYMS genotype was associated with both increased efficacy and toxicity of 5-FU therapy in colon cancer patients [22] . Further support for this strategy was Despite the potential benefits demonstrated in colorectal cancer patients, the use of this strategy for second-line pancreatic adenocarcinoma therapy proved to be very difficult. One of the primary problems associated with this approach was obtaining appropriate patient enrollment to adequately perform the treatment portion of the study. Unfortunately, of the 16 patients that possessed this genotype, only four patients were enrolled in the study.
The predominant difficulty associated with enrollment to the treatment portion of the study was the extremely poor prognosis of pancreatic cancer patients requiring secondline therapy. Many of the patients who progressed on gemcitabine were too ill to be enrolled to the treatment portion of the study. Another issue was the number of additional second-line clinical trials open at the institution during the period of patient enrollment onto this study. Lastly, many patients were treated with capecitabine by their local oncologist instead of enrolling on the clinical trial, since they could obtain the drug at their local pharmacy without having to travel to a tertiary care center. While genotype-directed therapy represents a novel approach to the treatment of pancreatic cancer patients, it is difficult to conduct such a study in the second line setting for this patient population, especially with a drug than can easily be used off-label. This strategy may prove to be a more useful treatment strategy either in the adjuvant setting or for first-line metastatic disease. Despite the small sample size of the treatment portion, the observed toxicity was impressive. All subjects experienced significant grade 2 and 3 non-hematologic toxicity with exposure to capecitabine. The predominant grade 2 and 3 toxicities were diarrhea, nausea/vomiting, hand and foot syndrome and mucositis. One patient was hospitalized due to grade 3 nausea/vomiting, hand and foot syndrome and diarrhea. This was not explained by patient fitness, since all patients had a performance status of ECOG ≤1 at time of study entry. In addition, all patients except the one patient who died while on study were treated on subsequent clinical trials. The limited data gathered in this study would suggest that pharmacokinetic variability in the studied patient population compared to an unselected patient population did not explain the increase observed toxicity. Exposure levels of capecitabine or 5-FU have not been reported in previous studies evaluating the pharmacogenetics of TYMS as it applies to various forms of 5-FU based chemotherapy. The findings of this study would suggest that other factors such as additional polymorphisms involving other genes important for 5-FU metabolism or pharmacodynamics may be interacting with the TYMS*2 to drive the profound level of toxicity. However, interpretation of these results is limited by the sample size of the study.
Gemcitabine represents the standard of care for patients with advanced pancreatic cancer. The single nucleotide polymorphisms ATM G60A and RecQ1 A159C have previously been demonstrated to be associated with poor overall survival in those patients receiving neoadjuvant gemcitabine-based therapy for resectable early stage pancreatic adenocarcinoma [25, 26] . This study attempted to extend these findings to the metastatic disease setting, but no statistically significant relationship between ATM, RecQ1 and TYMS genotypes and overall survival were observed. However, despite the limited number of subjects, there did appear to be a trend toward poorer overall survival in patients with metastatic pancreatic cancer possessing the TYMS *2/*2 genotype treated with gemcitabine. This may be more reflective of TYMS genotype association with specific stages of malignancy as has been shown for squamous cell carcinoma of head and neck, colon cancer and non-small cell lung cancer than a direct impact on pathways responsible for gemcitabine-induced cell death [34] [35] [36] . This observation is also confounded by the wide variety of first-line therapy these patients received. Recently, SNPs involving a combination of genes involved in gemcitabine transport and metabolism have been associated with survival in patients treated with neoadjuvant gemcitabine-based chemoradiotherapy [37] . These results have not been extended to the metastatic disease setting. These findings suggest that genotype-directed therapy may have a role in determining which patients should receive gemcitabine neoadjuvant therapy but cannot be extended to guide the use of gemcitabine in the metastatic disease setting.
In summary, large studies of genotype-directed therapy for second-line pancreatic adenocarcinoma therapy are difficult to perform successfully, particularly when the investigational agent is available off-study. The poor natural history of this patient population also presents a significant challenge. Therefore application of this strategy may be better utilized in the adjuvant or first-line metastatic disease setting, or with an agent not yet FDA-approved. Another significant limitation to this study was that it was performed as a single institution study. A multi-institutional study would allow for the screening of a larger number of patients, but obtaining funding for such studies can be challenging. Overcoming these obstacles will be important for implementation of genotype-directed therapy and other designs that ultimately may result in the realization of personalized therapy for pancreatic cancer patients. 
